Journal Article10.1186/s12967-025-06645-6
Fecal microbiota transplantation from patients into animals to establish human microbiota-associated animal models: a scoping review
Jakub Ruszkowski,Zofia Kachlik,Michał Walaszek,Dawid Storman,Karolina Podkowa,Paweł Garbarczuk,Paweł Jemioło,Weronika Łyzińska,Katarzyna Nowakowska,Konrad Grych,Alicja Dębska‐Ślizień +10 more
4
TL;DR: A scoping review of 605 reports on fecal microbiota transplantation from humans to animals found that inflammatory bowel diseases, obesity, and cancer were commonly studied, with gastrointestinal outcomes being most frequently reported, highlighting the need for standardized protocols.
read more
Abstract: Abstract Background Fecal microbiota transplantation (FMT) from humans with specific medical conditions to animal models can demonstrate causality by inducing or exacerbating pathophenotypes, linking the gut microbiota to health outcomes. Methods We conducted a scoping review searching MEDLINE, EMBASE, Scopus, and Web of Science through July 2024 to identify human noninfectious diseases studied using FMT in animal models, investigate FMT methodologies, and assess the feasibility of systematic reviews on the role of the microbiota in specific diseases. Results From 605 reports of 489 studies, we found that inflammatory bowel diseases, irritable bowel syndrome, obesity, colorectal cancer, and depression were the most commonly studied, with cancer research focusing on immunotherapy non-responsiveness. In a random sample of studies, gastrointestinal outcomes were most frequently reported, with remarkably high rates (> 80%) of successful induction of disease-specific alterations for intestinal barrier function, gastrointestinal inflammation, circulating immune parameters, and fecal metabolites. Most studies used C57BL/6 mice and oral gavage administration, with recipients being either germ-free or antibiotic-pretreated. We created tables linking conditions with publications to facilitate future systematic reviews. Conclusions Although human-to-animal FMT studies cover diverse conditions, methodological heterogeneity and inconsistent reporting hinder comparability. Standardized protocols and guidelines are needed. For several conditions, sufficient literature exists to assess the role of the gut microbiota in human health through systematic reviews.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Gut microbiota links to cognitive impairment in bipolar disorder via modulating synaptic plasticity
Anying Tang,H. Jiang,Jie Li,Yi Chen,Jinyu Zhang,Dandan Wang,Shaohua Hu,Jianbo Lai +7 more
TL;DR: This study links gut microbiota to cognitive impairment in bipolar disorder by modulating synaptic plasticity, revealing distinct microbial compositions in patients with and without cognitive impairment, and demonstrating that gut microbiota transplantation and supplementation can influence cognitive and emotional phenotypes in mice.
1
Assessment of ecological fidelity of human microbiome-associated mice in observational studies and an interventional trial
Matthew K. Wong,Eric Armstrong,Alya Heirali,Pierre H. H. Schneeberger,Helen Chen,Kyla Cochrane,Keith Sherriff,Emma Allen‐Vercoe,Lillian L. Siu,Anna Spreafico,Bryan Coburn +10 more
TL;DR: Human microbiota-associated (HMA) mouse models, used to study gut microbiome effects, are limited in ecological fidelity, resembling other mice more than their human donors, with a restricted set of microbes engrafting regardless of exposure route.
Human-associated gut bacterial dysbiosis affects the anti-colitic activity of 3-DF and 3-HF
José Antonio Haro-Reyes,Jayaprakash Kanijam Raghupathi,Bruce Hamaker,Lavanya Reddivari +3 more
Abstract: Effects of flavonoid-rich diets in recipients depended on the microbial composition of the dysbiotic donor.
The Ambivalent Nature of Bacteroides fragilis and the Interaction with Clostridioides difficile: Benefits and Disadvantages for the Human Host
Abstract: Bacteroides fragilis is a usually beneficial colonizer of the human gut that can also act as an opportunistic pathogen, causing infection and contributing to the development and progression of important diseases. The production and secretion of the B. fragilis toxin (BFT), the main virulence factor of this bacterium, distinguishes enterotoxigenic (ETBF) from non-toxigenic (NTBF) strains. Although NTBF does not produce the BFT, certain strains can exhibit unexpected pathogenic characteristics. The complex interactions between B. fragilis and the other intestinal bacteria, such as Clostridioides difficile, the leading cause of antibiotic-associated diarrhea in healthcare settings, highlights its ambivalent role of benefactor and pathogen. In fact, although B. fragilis plays a part in preventing colonization and infection due to C. difficile (CDI), both these anaerobic bacteria can contribute to the development and progression of colorectal cancer (CRC), one of the most prevalent malignant tumors of the digestive tract. This review provides an overview of the dual nature of B. fragilis, focusing on the peculiarities of ETBF and NTBF, delving into B. fragilis interaction with C. difficile and impacts on the host.